Please assess the completion status of the following clinical trial:

Trial Title: Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign an Institutional Review Board (IRB)-approved informed consent document.~2. Age \>/= than18 years~3. de novo or secondary International Prostate Symptom Score (IPSS) low- or intermediate-1 - risk MDS, including CMML~4. Eastern Cooperative Oncology Group (ECOG) performance status of \</= 3 at study entry.~5. Organ function as defined: Serum creatinine \</= 3 x Upper Limit of Normal (ULN), Total bilirubin \</= 2 x ULN, Alanine transaminase (ALT) (SGPT) \</= 2 x ULN~6. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and will also need to use contraceptives. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.~Exclusion Criteria:~1. Breast feeding females~2. Prior therapy with decitabine or azacitidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
- Azacitidine (Type: EXPERIMENTAL): Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).